TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Predictive Oncology ( (POAI) ).
On October 29, 2025, Predictive Oncology Inc. filed a prospectus supplement to update its at-the-market (ATM) offering program, allowing the sale of up to $18,330,000 in common stock. This move aims to adjust the maximum share sales under the ATM program, contingent on changes in the company’s public float, which could impact its ability to raise capital and expand its operations.
The most recent analyst rating on (POAI) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Predictive Oncology stock, see the POAI Stock Forecast page.
Spark’s Take on POAI Stock
According to Spark, TipRanks’ AI Analyst, POAI is a Neutral.
The overall stock score is heavily influenced by the company’s poor financial performance, characterized by declining revenues and negative profit margins. Technical analysis indicates a bearish trend with weak momentum, while valuation metrics are unattractive due to negative earnings and no dividend yield. These factors collectively result in a low overall score.
To see Spark’s full report on POAI stock, click here.
More about Predictive Oncology
Predictive Oncology Inc. is a Delaware-based company involved in the biotechnology sector, focusing on leveraging data and artificial intelligence to develop personalized cancer therapies. The company operates within the healthcare industry, aiming to enhance treatment outcomes through predictive modeling and advanced analytics.
Average Trading Volume: 89,458
Technical Sentiment Signal: Strong Sell
Current Market Cap: $40.81M
For an in-depth examination of POAI stock, go to TipRanks’ Overview page.